142 related articles for article (PubMed ID: 20206498)
21. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
23. Expression of cell regulatory proteins in ovarian borderline tumors.
van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
[TBL] [Abstract][Full Text] [Related]
24. p63 expression in ovarian tumours: a marker for Brenner tumours but not transitional cell carcinomas.
Liao XY; Xue WC; Shen DH; Ngan HY; Siu MK; Cheung AN
Histopathology; 2007 Oct; 51(4):477-83. PubMed ID: 17880529
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
26. Free radicals, metals and antioxidants in oxidative stress-induced cancer.
Valko M; Rhodes CJ; Moncol J; Izakovic M; Mazur M
Chem Biol Interact; 2006 Mar; 160(1):1-40. PubMed ID: 16430879
[TBL] [Abstract][Full Text] [Related]
27. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
28. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
29. Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis.
Karihtala P; Winqvist R; Syväoja JE; Kinnula VL; Soini Y
Eur J Cancer; 2006 Oct; 42(15):2653-9. PubMed ID: 16996262
[TBL] [Abstract][Full Text] [Related]
30. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.
Warrenfeltz S; Pavlik S; Datta S; Kraemer ET; Benigno B; McDonald JF
Mol Cancer; 2004 Oct; 3():27. PubMed ID: 15471544
[TBL] [Abstract][Full Text] [Related]
31. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
Jordan SJ; Green AC; Whiteman DC; Webb PM;
Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
[TBL] [Abstract][Full Text] [Related]
33. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
[TBL] [Abstract][Full Text] [Related]
34. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer.
Woolston CM; Storr SJ; Ellis IO; Morgan DA; Martin SG
Radiother Oncol; 2011 Aug; 100(2):308-13. PubMed ID: 21641069
[TBL] [Abstract][Full Text] [Related]
35. Human ovarian tumors express gamma-glutamyl transpeptidase.
Hanigan MH; Frierson HF; Brown JE; Lovell MA; Taylor PT
Cancer Res; 1994 Jan; 54(1):286-90. PubMed ID: 7903206
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
[TBL] [Abstract][Full Text] [Related]
37. [Relationship between cyclooxygenase-2 protein expression, prostaglandins levels and biologic behavior in ovarian carcinoma tissue].
Tang L; Wang M; Ma J
Zhonghua Fu Chan Ke Za Zhi; 2002 Nov; 37(11):687-90. PubMed ID: 12487927
[TBL] [Abstract][Full Text] [Related]
38. Proteomic analysis of protein expression affected by peroxiredoxin V knock-down in hypoxic kidney.
Yang HY; Kwon J; Cho EJ; Choi HI; Park C; Park HR; Park SH; Chung KJ; Ryoo ZY; Cho KO; Lee TH
J Proteome Res; 2010 Aug; 9(8):4003-15. PubMed ID: 20553050
[TBL] [Abstract][Full Text] [Related]
39. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
40. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
